A new pressure-sensitive contact lens is tolerable and safe over a 24-hour wearing period for healthy subjects and glaucoma sufferers.
A new pressure-sensitive contact lens is tolerable and safe over a 24-hour wearing period for healthy subjects and glaucoma sufferers, according to a paper in the Journal of Glaucoma.
Dr Katrin Lorenz et al., Department of Ophthalmology, University Medical Centre, Johannes Gutenberg-University Mainz, Germany, included 20 healthy subjects and 20 age-matched glaucoma patients in a prospective, single-centre, open, observational parallel group study.
The study incorporated the Sensimed Triggerfish Sensor, a soft disposable contact lens embedded with a telemetry chip and strain gauge sensor for continuous IOP monitoring. The sensor was implanted in one eye of each patient for 24 hours. A visual analogue scale was used to evaluate tolerability. The safety parameters included best-corrected visual acuity, pachymetry, epithelial defects, conjunctival erythema and corneal topography.
The 24-hour wearing period was completed by 19 healthy participants and 19 glaucoma patients. Pain or inappropriate fitting of the sensor contributed towards early discontinuation. Mean tolerability was 21.8 in the healthy group and 26.8 in the glaucoma group.
Corneal epithelial staining increased from 0.4 and 1.0 at baseline to 1.8 and 2.8 in the healthy and glaucoma groups, respectively. There were no statistically differences between the two groups, meaning they both had a similar safety and tolerability profiles.
To read the abstract please click here.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.